太阴病论治结直肠癌围化疗期的感悟
The Perception of the Treatment Method of the Taiyin Disease in the Peri-Chemotherapy Period of Colorectal Cancer
DOI: 10.12677/TCM.2021.103061, PDF,   
作者: 纪丽芝:广州中医药大学,广东 广州;蒋 梅:广州中医药大学第一附属医院,广东 广州
关键词: 伤寒论太阴病结直肠癌化疗Typhoid Taiyin Disease Colorectal Cancer Chemotherapy
摘要: 化疗在结直肠癌的分期治疗中具有较广泛的应用,且取得了公允的较大获益。但化疗在改善结直肠癌患者生存状况的同时,也造成了包括胃肠道反应在内的多种毒副作用,中医药的介入能有效地改善人体对化疗药物的耐受并提高化疗效果。师法经典,笔者发现《伤寒论》中的太阴病与结直肠癌患者围化疗期的病情存在病位、病性、病机上的相似,故在结直肠癌围化疗期的分期证治中,可借鉴太阴病的治则治法:温中为主,兼顾肝肾,此外还发现太阴病的时间规律对结直肠癌的时间化疗亦有启发,由此可见经典指导临床的意义及发掘经典价值的必要性。
Abstract: Chemotherapy has been widely used in staging treatment of colorectal cancer, and has achieved a fair and large benefit. However, chemotherapy has not only improved the survival condition of colorectal cancer patients, but also caused a variety of toxic and side effects including gastrointestinal reactions. TCM intervention can effectively improve the human body’s tolerance to chemotherapy drugs and improve the effect of chemotherapy. According to the classic method, we found that the condition of Taiyin disease in the typhoid theory and the condition of colorectal cancer patients in the peri-chemotherapy period are similar in the disease location and pathogenesis. Therefore, in the treatment of stage syndrome in the peri-chemotherapy period of colorectal cancer, the treatment method of Taiyin disease can be used for reference: temperature-centered, giving consideration to both liver and kidney. In addition, we also found that the regularity of the time of Taiyin disease is also enlightening to the time chemotherapy of colorectal cancer. Thus, it can be seen the significance of classical guidance in clinical practice and the necessity of exploring classical value.
文章引用:纪丽芝, 蒋梅. 太阴病论治结直肠癌围化疗期的感悟[J]. 中医学, 2021, 10(3): 440-445. https://doi.org/10.12677/TCM.2021.103061

参考文献

[1] Leijssen, L.G.J., Dinaux, A.M., Taylor, M.S., Deshpande, V., Hiroko, K., Bordeianou, L.G., et al. (2019) Perineural Invasion Is a Prognostic but Not a Predictive Factor in Nonmetastatic Colon Cancer. Diseases of the Colon & Rectum, 62, 1212-1221. [Google Scholar] [CrossRef
[2] 魏哲威, 张常华, 余捷, 吴菁, 何裕隆. 含奥沙利铂辅助化疗方案治疗结直肠癌可切除肝转移的预后分析[J]. 热带医学杂志, 2018, 18(9): 1156-1159, 1181.
[3] Ouyang, M., Luo, Z., Wu, J., Zhang, W., Tang, S., Lu, Y., et al. (2019) Comparison of Outcomes of Complete Mesocolic Excision with Conventional Radical Resection Performed by Laparoscopic Approach for Right Colon Cancer. Cancer Management and Research s, 25, 8647-8656. [Google Scholar] [CrossRef
[4] 吴福红, 孙元珏. XELOX与FOLFOX4方案治疗晚期结直肠癌的临床研究[J]. 医学信息(下旬刊), 2011, 24(18): 3-5.
[5] 徐俊, 陈旭. 结肠癌辅助化疗的研究进展[J]. 医学综述, 2017, 23(20): 4039-4044.
[6] 徐瑞华, 邱妙珍. 晚期结直肠癌化疗的研究进展[J]. 癌症, 2008, 27(6): 661-666.
[7] Wang, D. and Fu, J. (2014) Symptom Clusters and Quality of Life in China Patients with Lung Cancer Undergoing Chemotherapy. African Health Sciences, 14, 49-55. [Google Scholar] [CrossRef] [PubMed]
[8] 郭兴罡, 赵智辅, 陈杰, 庄海英. 顺铂化疗过程中联合应用大剂量止吐药预防胃肠道反应[J]. 黑龙江医学, 2000(4): 30.
[9] 林万隆, 陈强. 奥沙利铂的药理作用及临床应用[J]. 中国肿瘤临床, 2000, 27(11): 872-874.
[10] 潘建军. 肿瘤放化疗所引起腹泻两种治疗方法比较分析[J]. 求医问药(下半月), 2011, 9(11): 563.
[11] 朱一玢. 时辰化疗结合择时用药缓解肠癌术后化疗胃肠反应的研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2013.
[12] 曹迪, 张亚密, 全建峰. 中医药改善化疗毒副反应的研究进展[J]. 中国中医急症, 2020, 29(7): 1302-1305, 1308.
[13] Kumamoto, K., Nakachi, Y., Mizuno, Y., Yokoyama, M., Ishibashi, K., Kosugi, C., et al. (2019) Expressions of 10 Genes as Candidate Predictors of Recurrence in Stage Ⅲ Colon Cancer Patients Receiving Adjuvant Oxaliplatin-Based Chemotherapy. Oncology Letters, 18, 1388-1394. [Google Scholar] [CrossRef] [PubMed]
[14] 徐萌, 王勇, 张梅, 胡金鹏, 李平. Ⅲ期结肠癌术后辅助化疗联合中药治疗的疗效研究[J]. 安徽医学, 2020, 41(3): 273-276.
[15] 林胜友, 沈敏鹤, 舒静娜, 蓝继. 780例大肠癌中医证型分类 特征的回顾性分析[J]. 浙江中医药大学学报, 2011, 35(3): 322-324.
[16] 侯风刚, 岑怡, 贯剑, 朱凌云, 殷晓聆, 刘静. 肠癌中医症状证候临床调查分析[J]. 辽宁中医药大学学报, 2010, 12(1): 32-34.
[17] Xu, S.Z. (2014) Clinical Study on Chemotherapy Induced Diarrhea in Colorectal cancer Patients. Zhejiang University, Hangzhou.
[18] 梅丹, 陆俊国, 顾海娟, 郭小红, 徐艳艳, 倪美鑫. 伊立替康化疗相关性腹泻发生的特点与危险因素分析[J]. 中国医院药学杂志, 2019, 39(2): 191-195.
[19] Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., et al. (2014) Guidance on the Management of Diarrhoea during Cancer Chemotherapy. The Lancet Oncology, 15, e447-e460. [Google Scholar] [CrossRef
[20] Yu, Q.Y., Wang, H.L., Wu, T., et al. (2012) A Case of Serious Adverse Effect Induced by Irinotecan. Chinese Journal of Pharmaceuticals, 32, 733-735.
[21] 张宇涛. 结直肠癌的治疗进展[J]. 山西医药杂志, 2020, 49(5): 535-536.
[22] Levi, F. (1999) Caner Chronotherapy. Journal of Pharmacy and Pharmacology, 51, 891-898. [Google Scholar] [CrossRef] [PubMed]